Search
Uniqure NV
QUREAdd to Watchlist
45.830USD
-0.230-0.50%
Market hours （ET）Quotes delayed by 15 min
2.89BMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
-0.50%
5 Days
-6.55%
1 Month
+60.64%
6 Months
+91.52%
Year to Date
+91.52%
1 Year
+228.77%
Key Figures
46.010Open
47.555High
493.06KVolume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
0.78%Turnover Ratio
46.060Prev. Close
45.790Low
16.85MTurnover
LossP/E Static
19.34P/B
0.00%Div Yield TTM
-30.18%ROA
71.50052wk High
0.31Volume Ratio
-239.56MNet Profit
63.03MShares
-3.4918EPS TTM
0.72Beta
-228.24%ROE
7.76052wk Low
3.83%Amplitude
93.85%Gross Margin
2.89BMarket Cap
10.09Reward/Risk
6.27%Risk Rate
TradingKey Stock Score of Uniqure NV
Currency: USD Updated: 2026-06-30Key Insights
Uniqure NV's fundamentals are relatively stable, and its growth potential is high.Its valuation is considered fairly valued, ranking 73 out of 387 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 64.83.In the medium term, the stock price is expected to trend up.Despite strong stock market performance and technicals over the past month, the fundamentals don't support the current trend.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Uniqure NV's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Positive
Uniqure NV Highlights
StrengthsRisks
Uniqure NV is a company based in the Netherlands specialized in gene therapy. It seeks to develop one-time administered treatments with potentially curative results for patients suffering from genetic and other devastating diseases. It develops, both internally and through partnerships, a pipeline of gene therapies. It produces adeno-associated virus based, or AAV-based, gene therapies in its own facilities with a proprietary, commercial-scale, current good manufacturing practices, compliant, manufacturing process. AMT-061, the Company’s lead product candidate for patients with hemophilia B, is going through a dosing phase of a pivotal study. AMT-130, the product candidate for patients with Huntington’s disease is in Phase I/II clinical study.
Growing
The company is in a growing phase, with the latest annual income totaling USD 16.10M.
Undervalued
The company’s latest PE is -13.19, at a low 3-year percentile range.
Institutional Buying
The latest institutional holdings are 65.80M shares, increasing 2.38% quarter-over-quarter.
Held by Lee Ainslie
Star Investor Lee Ainslie holds 453.32K shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 0.35.
Analyst Rating
Based on
15
analysts
Buy
Current Rating
64.833
Target Price
+36.81%
Upside Space
Uniqure NV News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Uniqure NV Info
Uniqure NV is a company based in the Netherlands specialized in gene therapy. It seeks to develop one-time administered treatments with potentially curative results for patients suffering from genetic and other devastating diseases. It develops, both internally and through partnerships, a pipeline of gene therapies. It produces adeno-associated virus based, or AAV-based, gene therapies in its own facilities with a proprietary, commercial-scale, current good manufacturing practices, compliant, manufacturing process. AMT-061, the Company’s lead product candidate for patients with hemophilia B, is going through a dosing phase of a pivotal study. AMT-130, the product candidate for patients with Huntington’s disease is in Phase I/II clinical study.
Ticker SymbolQURE
CompanyUniqure NV
CEOKapusta (Matthew)
Websitehttps://www.uniqure.com/
Related Instruments
-0.62%
-0.18%
-2.41%
-0.36%
-1.32%
-1.10%
-0.17%
+2.76%
+0.07%
-0.42%
+0.99%
-1.35%
-1.99%
-2.70%
+1.47%
0.00%
+0.80%
+0.36%
-2.80%
-0.36%Popular Instruments
52650.700
+454.400 (+0.87%)
29977.200
-247.400 (-0.82%)
7516.200
+33.800 (+0.45%)
15375.000
-220.000 (-1.41%)
69891.000
-965.000 (-1.36%)
6293.600
-33.400 (-0.53%)
68.158
-1.763 (-2.52%)
295.190
+5.830 (+2.01%)
196.850
-3.240 (-1.62%)
4077.680
+70.400 (+1.76%)
FAQs
What is the current price of Uniqure NV (QURE)?
The current price of Uniqure NV (QURE) is 46.06.
What is the symbol of Uniqure NV?
The ticker symbol of Uniqure NV is QURE.
What is the 52-week high of Uniqure NV?
The 52-week high of Uniqure NV is 71.50.
What is the 52-week low of Uniqure NV?
The 52-week low of Uniqure NV is 7.76.
What is the market capitalization of Uniqure NV?
The market capitalization of Uniqure NV is 3.13B.
Is Uniqure NV (QURE) currently rated as Buy, Hold, or Sell?
According to analysts, Uniqure NV (QURE) has an overall rating of Buy, with a price target of 64.83.
What is the Earnings Per Share (EPS TTM) of Uniqure NV (QURE)?
The Earnings Per Share (EPS TTM) of Uniqure NV (QURE) is -3.46.